Botulinum Toxin Type A: 4 agencies, 2010–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 8.8 years, from 27 Sep 2010 at AWMSG (Wales) to 2019 at PBAC (Australia).
AWMSG (Wales) changed its position: not recommended on 6 Dec 2013, recommended by 13 Dec 2013, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for botulinum toxin type a at all.
Not every gap is a refusal: for botulinum toxin type a, 3 submissions were never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2019; on this evidence the file is dormant.
The programme is broad: 12 distinct indication wordings are recorded for botulinum toxin type a by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess botulinum toxin type a, on 27 Sep 2010; PBAC (Australia) did not open a file until 2017 — a wide spread of 6.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 4 agencies here assessed botulinum toxin type a more than once, SMC (Scotland) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed botulinum toxin type a.
The full ledger for botulinum toxin type a reads 6 recommended, 3 non-submission, 2 restricted and 1 deferred, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2019 | Spasticity of the upper limb | The PBAC recommended the extension of the current Section 100 (Botulinum Toxin Program) Au… | source |
| SMC (Scotland) | 7 Jul 2014 | The management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, u… | accepted (restricted) | source |
| SMC (Scotland) | 7 Jul 2014 | Focal lower limb spasticity, including the treatment of ankle disability due to lower limb spasticity associated with stroke in adults. | not recommended | source |
| AWMSG (Wales) | 6 Dec 2013 | Management of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who are … | not endorsed (non-submission) | source |
| NICE (England) | 27 Jun 2012 | NICE TA260 | recommended (optimised) | source |
9 further decisions for botulinum toxin type a, across 3 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- rocuronium — same ATC class M03A — Muscle relaxants
- dapagliflozin — also decided by SMC in 2014Q3
- tocilizumab — also decided by SMC in 2014Q3
- certolizumab pegol — also decided by SMC in 2014Q3
- ocriplasmin — also decided by SMC in 2014Q3
- alemtuzumab — also decided by SMC in 2014Q3
Coverage: 14 decisions for botulinum toxin type a from 4 agencies, 2010 to 2019. Data to 7 Sep 2026. ATC class M03A — Muscle relaxants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.